Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies – implications for solid tumors and potential for therapeutic inhibition

References

• Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, et al. 2006. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12:353–360
   PubMed Web of Science ®Google Scholar
• Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. 2007. Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers. Ann Oncol 18:485–490
   PubMed Web of Science ®Google Scholar
• Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. 2008. Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers. Br J Cancer 98:845–851
   Google Scholar
• Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. 2009. Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers. Gynecol Oncol 114:84–88
   PubMed Web of Science ®Google Scholar
• Batlle E, Bacani J, Beghtel H, Jonkheer S, Jonkeer S, Gregorieff A, van de Born M, et al. 2005. EphB receptor activity suppresses colorectal cancer progression. Nature 435:1126–1130
   PubMed Web of Science ®Google Scholar
• Berclaz G, Karamitopoulou E, Mazzucchelli L, Rohrbach V, Dreher E, Ziemiecki A, Andres A-C. 2003. Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. Ann Oncol 14:220–226
   Google Scholar
• Blume-Jensen P, Hunter T. 2001. Oncogenic kinase signalling. Nature 411:355–365
   PubMed Web of Science ®Google Scholar
• Blumenschein GR, Mills GB, Gonzalez-Angulo AM. 2012. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 30:3287–3296
   PubMed Web of Science ®Google Scholar
• Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, Chen J. 2011. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS ONE 6:e24426
   PubMed Web of Science ®Google Scholar
• Chetcuti A, Aktas S, Mackie N, Ulger C, Toruner G, Alkan M, Catchpoole D. 2011. Expression profiling reveals MSX1 and EphB2 expression correlates with the invasion capacity of Wilms tumors. Pediatr Blood Cancer 57:950–957
   Google Scholar
• Choong NW, Cohen EEW. 2006. Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol 57:25–43
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. 2003. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980–1987
   PubMed Web of Science ®Google Scholar
• Cooper JB, Cohen EEW. 2009. Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head Neck 31:1086–1094
   PubMed Web of Science ®Google Scholar
• Ferguson BD, Liu R, Rolle CE, Tan Y-HC, Krasnoperov V, Kanteti R, Tretiakova MS, et al. 2013. The EphB4 receptor tyrosine kinase promotes lung cancer growth: A potential novel therapeutic target. PLoS ONE 8:e67668
   Google Scholar
• Guijarro-Muñoz I, Sánchez A, Martínez-Martínez E, García JM, Salas C, Provencio M, Álvarez-Vallina L, Sanz L. 2013. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol 30:572–579
   PubMedGoogle Scholar
• Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, et al. 2004. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50:490–499
   PubMed Web of Science ®Google Scholar
• Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, et al. 2013. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res 73:184–194
   PubMedGoogle Scholar
• Kullander K, Klein R. 2002. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475–486
   PubMed Web of Science ®Google Scholar
• Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, et al. 2007. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer 96:1083–1091
   Google Scholar
• Kumar SR, Scehnet JS, Ley EJ, Singh J, Krasnoperov V, Liu R, Manchanda PK, et al. 2009. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res 69:3736–3745
   PubMed Web of Science ®Google Scholar
• Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Scehnet J, et al. 2006. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 169:279–293
   PubMed Web of Science ®Google Scholar
• Lee Y-C, Perren JR, Douglas EL, Raynor MP, Bartley MA, Bardy PG, Stephenson S-A. 2005. Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma. BMC Cancer 5:119–129
   Google Scholar
• Li G, Ji X-D, Gao H, Zhao J-S, Xu J-F, Sun Z-J, Deng Y-Z, et al. 2012. EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex. Nat Commun 3:667–676
   Google Scholar
• Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V. 2013. EphB4 as a therapeutic target in mesothelioma. BMC Cancer 13:269–275
   Google Scholar
• Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, et al. 2006. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer 119:1236–1248
   PubMed Web of Science ®Google Scholar
• Ozgür E, Heidenreich A, Dagtekin O, Engelmann U, Bloch W. 2011. Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue. Urol Oncol 29:78–84
   PubMed Web of Science ®Google Scholar
• Price KAR, Cohen EE. 2012. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13:35–46
   PubMed Web of Science ®Google Scholar
• Roskoski R. 2013. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79C:34–74
   Google Scholar
• Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, Dinali el M, Yala S, et al. 2009. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021–3031
   PubMed Web of Science ®Google Scholar
• Sharma GK, Dhillon VK, Masood R, Maceri DR. 2014. Overexpression of EphB4, EphrinB2 and EGFR in papillary thyroid carcinoma: A pilot study. Head Neck. [Epub ahead of print]
   Google Scholar
• Sinha UK, Kundra A, Scalia P, Smith DL, Parsa B, Masood R, Gill PS. 2003. Expression of EphB4 in head and neck squamous cell carcinoma. Ear Nose Throat J 82:866–887
   Google Scholar
• Sinha UK, Mazhar K, Chinn SB, Dhillon VK, Liu L, Masood R, Rice DH, Gill PS. 2006. The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132:1053–1059
   Google Scholar
• Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MMK, Lee S-J, et al. 2010. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 9:2377–2388
   PubMed Web of Science ®Google Scholar
• Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE. 2001. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2:15–23
   Google Scholar
• Steube KG, Meyer C, Habig S, Uphoff CC, Drexler HG. 1999. Expression of receptor tyrosine kinase HTK (hepatoma transmembrane kinase) and HTK ligand by human leukemia-lymphoma cell lines. Leuk Lymphoma 33:371–376
   PubMed Web of Science ®Google Scholar
• Wagh PK, Peace BE, Waltz SE. 2008. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 100:1–33
   PubMed Web of Science ®Google Scholar
• Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, Wu B, Mitra S, et al. 2013. Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res 19:128–137
   PubMed Web of Science ®Google Scholar
• Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM. 2006. The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol 102:15–21
   Google Scholar
• Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. 2004. Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res 10:26–33
   PubMed Web of Science ®Google Scholar
• Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, et al. 2005. EphB4 expression and biological significance in prostate cancer. Cancer Res 65:4623–4632
   PubMed Web of Science ®Google Scholar
• Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, Hassanieh L, et al. 2006. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 25:769–780
   PubMed Web of Science ®Google Scholar
• Yang N-Y, Pasquale EB, Owen LB, Ethell IM. 2006. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization. J Biol Chem 281:32574–32586
   PubMedGoogle Scholar
• Yavrouian EJ, Sinha UK, Rice DH, Salam MT, Gill PS, Masood R. 2008. The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 134:985–991
   PubMed Web of Science ®Google Scholar